Chao-Yie Yang

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5002740/chao-yie-yang-publications-by-year.pdf
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99 papers	5,862 citations	44 h-index	75 g-index
112 ext. papers	6,952 ext. citations	7.2 avg, IF	5.66 L-index

#	Paper	IF	Citations
99	Design, Synthesis, and Biological Evaluation of Apcin-Based CDC20 Inhibitors.. *ACS Medicinal Chemistry Letters*, **2022**, 13, 188-195	4.3	0
98	The Similarity of Class II HLA Genotypes Defines Patterns of Autoreactivity in Idiopathic Bone Marrow Failure Disorders. *Blood*, **2021**,	2.2	2
97	Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression. *Journal of Medicinal Chemistry*, **2021**, 64, 14540-14556	8.3	7
96	SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression. *ACS Medicinal Chemistry Letters*, **2021**, 12, 996-1004	4.3	3
95	Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity. *Nature Communications*, **2021**, 12, 2621	17.4	1
94	Comparative Analyses of the Conformational Dynamics Between the Soluble and Membrane-Bound Cytokine Receptors. *Scientific Reports*, **2020**, 10, 7399	4.9	4
93	Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein. *Journal of Medicinal Chemistry*, **2020**, 63, 7510-7528	8.3	38
92	Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application. *Journal of Medicinal Chemistry*, **2020**, 63, 11368-11396	8.3	49
91	EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development. *Journal of Medicinal Chemistry*, **2020**, 63, 7252-7267	8.3	14
90	Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway. *Advances in Experimental Medicine and Biology*, **2020**, 1217, 349-362	3.6	3
89	N-terminal modified cyclopeptidic mimetics of Apollo as inhibitors of TRF2. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127401	2.9	0
88	Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. *Journal of Medicinal Chemistry*, **2020**, 63, 13994-14016	8.3	7
87	Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders. *Journal of Medicinal Chemistry*, **2019**, 62, 9471-9487	8.3	54
86	Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. *Drug Discovery Today: Technologies*, **2019**, 31, 43-51	7.1	59
85	A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. *Cancer Cell*, **2019**, 36, 498-511.e17	24.3	181
84	Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein. *Journal of Medicinal Chemistry*, **2019**, 62, 11280-11300	8.3	75
83	Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. *Journal of Medicinal Chemistry*, **2019**, 62, 11218-11231	8.3	61

82	Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). *Journal of Medicinal Chemistry*, **2019**, 62, 1420-1442	8.3	106
81	Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. *Journal of Medicinal Chemistry*, **2019**, 62, 941-964	8.3	157
80	Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. *Journal of Medicinal Chemistry*, **2019**, 62, 448-466	8.3	132
79	High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2018**, 61, 1934-1950	8.3	31
78	Cyclic Peptidic Mimetics of Apollo Peptides Targeting Telomeric Repeat Binding Factor 2 (TRF2) and Apollo Interaction. *ACS Medicinal Chemistry Letters*, **2018**, 9, 507-511	4.3	5
77	Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. *Journal of Medicinal Chemistry*, **2018**, 61, 462-481	8.3	197
76	Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. *Journal of Medicinal Chemistry*, **2018**, 61, 6110-6120	8.3	15
75	Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. *Journal of Medicinal Chemistry*, **2018**, 61, 6685-6704	8.3	133
74	From proteomics to discovery of first-in-class ST2 inhibitors active in vivo. *JCI Insight*, **2018**, 3,	9.9	20
73	MCL-1 inhibition in cancer treatment. *OncoTargets and Therapy*, **2018**, 11, 7301-7314	4.4	79
72	Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. *Cancer Research*, **2017**, 77, 2476-2487	12.6	115
71	Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. *Cold Spring Harbor Perspectives in Medicine*, **2017**, 7,	5.4	137
70	Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED). *Journal of Medicinal Chemistry*, **2017**, 60, 2212-2214	8.3	8
69	Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. *Journal of Medicinal Chemistry*, **2017**, 60, 3887-3901	8.3	23
68	A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation. *Nature Communications*, **2017**, 8, 1150	17.4	48
67	Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors. *ACS Medicinal Chemistry Letters*, **2016**, 7, 1092-1096	4.3	9
66	Design of High-Affinity Stapled Peptides To Target the Repressor Activator Protein 1 (RAP1)/Telomeric Repeat-Binding Factor 2 (TRF2) Protein-Protein Interaction in the Shelterin Complex. *Journal of Medicinal Chemistry*, **2016**, 59, 328-34	8.3	15
65	Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain. *PLoS ONE*, **2016**, 11, e0146522	3.7	7

64	Small Molecule ST2 Inhibitors Cause Reduction of Soluble ST2 and Improve Gvhd and Survival In Vivo. *Blood*, **2016**, 128, 528-528	2.2	
63	Enrichment of druggable conformations from apo protein structures using cosolvent-accelerated molecular dynamics. *Biology*, **2015**, 4, 344-66	4.9	16
62	Structure-Based Design of β-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. *Journal of Medicinal Chemistry*, **2015**, 58, 4927-39	8.3	66
61	Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method. *PLoS ONE*, **2015**, 10, e0118671	3.7	22
60	Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment. *PLoS ONE*, **2015**, 10, e0128807	3.7	19
59	Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells. *ACS Chemical Biology*, **2014**, 9, 994-1002	4.9	26
58	RNF111-dependent neddylation activates DNA damage-induced ubiquitination. *Molecular Cell*, **2013**, 49, 897-907	17.6	93
57	A potent and highly efficacious Bcl-2/Bcl-xL inhibitor. *Journal of Medicinal Chemistry*, **2013**, 56, 3048-3067	8.3	31
56	The making of I-BET762, a BET bromodomain inhibitor now in clinical development. *Journal of Medicinal Chemistry*, **2013**, 56, 7498-500	8.3	65
55	The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response. *Genes and Development*, **2013**, 27, 1752-68	12.6	107
54	Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants. *Angewandte Chemie - International Edition*, **2013**, 52, 8387-90	16.4	25
53	Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. *Journal of Mammary Gland Biology and Neoplasia*, **2012**, 17, 217-28	2.4	33
52	Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression. *Journal of Medicinal Chemistry*, **2012**, 55, 8502-14	8.3	44
51	Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold. *Journal of Medicinal Chemistry*, **2012**, 55, 4664-82	8.3	55
50	Analysis of Flexibility and Hotspots in Bcl-xL and Mcl-1 Proteins for the Design of Selective Small-Molecule Inhibitors. *ACS Medicinal Chemistry Letters*, **2012**, 3, 308-12	4.3	30
49	Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents. *Journal of Medicinal Chemistry*, **2012**, 55, 106-14	8.3	29
48	Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. *Journal of Medicinal Chemistry*, **2012**, 55, 1137-46	8.3	195
47	Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity. *Journal of Medicinal Chemistry*, **2012**, 55, 6149-61	8.3	43

46	LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNF expression and receptor tyrosine kinase signaling. *Cancer Research*, **2012**, 72, 1229-38	10.1	31
45	A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. *Journal of Medicinal Chemistry*, **2011**, 54, 2714-26	8.3	207
44	Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity. *Journal of Medicinal Chemistry*, **2011**, 54, 3306-18	8.3	38
43	Hydrophobic Binding Hot Spots of Bcl-xL Protein-Protein Interfaces by Cosolvent Molecular Dynamics Simulation. *ACS Medicinal Chemistry Letters*, **2011**, 2, 280-4	4.3	45
42	CSAR benchmark exercise of 2010: selection of the protein-ligand complexes. *Journal of Chemical Information and Modeling*, **2011**, 51, 2036-46	6.1	102
41	Correction to CSAR Benchmark Exercise of 2010: Selection of the Protein Ligand Complexes. *Journal of Chemical Information and Modeling*, **2011**, 51, 2146-2146	6.1	4
40	CSAR benchmark exercise of 2010: combined evaluation across all submitted scoring functions. *Journal of Chemical Information and Modeling*, **2011**, 51, 2115-31	6.1	117
39	Computational modeling toward understanding agonist binding on dopamine 3. *Journal of Chemical Information and Modeling*, **2010**, 50, 1633-43	6.1	15
38	Computational analysis of protein hotspots. *ACS Medicinal Chemistry Letters*, **2010**, 1, 125-9	4.3	24
37	Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. *Journal of Medicinal Chemistry*, **2010**, 53, 6361-7	8.3	39
36	Cyclopeptide Smac mimetics as antagonists of IAP proteins. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3043-6	2.9	31
35	Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases. *Journal of Medicinal Chemistry*, **2009**, 52, 593-6	8.3	38
34	Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction. *Journal of the American Chemical Society*, **2009**, 131, 13709-21	16.4	59
33	Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). *Journal of Medicinal Chemistry*, **2008**, 51, 7169-80	8.3	72
32	Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases. *Journal of Medicinal Chemistry*, **2008**, 51, 7352-5	8.3	34
31	Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile. *Journal of Medicinal Chemistry*, **2008**, 51, 5905-8	8.3	27
30	Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. *Journal of Medicinal Chemistry*, **2008**, 51, 717-20	8.3	67
29	Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases. *Journal of Medicinal Chemistry*, **2008**, 51, 8158-62	8.3	45

28	Interaction of a cyclic, bivalent smac mimetic with the x-linked inhibitor of apoptosis protein. *Biochemistry*, **2008**, 47, 9811-24	3.2	48
27	Design of small-molecule peptidic and nonpeptidic Smac mimetics. *Accounts of Chemical Research*, **2008**, 41, 1264-77	24.3	124
26	Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. *Journal of Medicinal Chemistry*, **2007**, 50, 1723-6	8.3	40
25	Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. *Journal of the American Chemical Society*, **2007**, 129, 15279-94	16.4	175
24	Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. *Journal of Medicinal Chemistry*, **2007**, 50, 3163-6	8.3	36
23	Design and synthesis of a new, conformationally constrained, macrocyclic small-molecule inhibitor of STAT3 via Sclick chemistryS *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 3939-42	2.9	50
22	A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells. *Annals of Hematology*, **2007**, 86, 471-81	3	13
21	Analysis of ligand-bound water molecules in high-resolution crystal structures of protein-ligand complexes. *Journal of Chemical Information and Modeling*, **2007**, 47, 668-75	6.1	134
20	Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. *Journal of Medicinal Chemistry*, **2006**, 49, 7916-20	8.3	93
19	Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes. *Journal of the American Chemical Society*, **2006**, 128, 11830-9	16.4	80
18	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. *Journal of Medicinal Chemistry*, **2006**, 49, 6139-42	8.3	257
17	M-score: a knowledge-based potential scoring function accounting for protein atom mobility. *Journal of Medicinal Chemistry*, **2006**, 49, 5903-11	8.3	62
16	Chapter 11 Recent Advances in Design of Small-Molecule Ligands to Target ProteinPProtein Interactions. *Annual Reports in Computational Chemistry*, **2006**, 197-219	1.8	1
15	The PDBbind database: methodologies and updates. *Journal of Medicinal Chemistry*, **2005**, 48, 4111-9	8.3	462
14	Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands. *Journal of Medicinal Chemistry*, **2005**, 48, 3171-81	8.3	24
13	A systematic analysis of the effect of small-molecule binding on protein flexibility of the ligand-binding sites. *Journal of Medicinal Chemistry*, **2005**, 48, 5648-50	8.3	15
12	Design and synthesis of a potent biotinylated Smac mimetic. *Tetrahedron Letters*, **2005**, 46, 7015-7018	2	2
11	Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 793-7	2.9	48

10	Solution Conformations of Wild-Type and Mutated Bak BH3 Peptides via Dynamical Conformational Sampling and Implication to Their Binding to Antiapoptotic Bcl-2 Proteins. *Journal of Physical Chemistry B*, **2004**, 108, 1467-1477	3.4	6
9	Structure-based discovery of nonpeptidic small organic compounds to block the T cell response to myelin basic protein. *Journal of Medicinal Chemistry*, **2004**, 47, 4989-97	8.3	31
8	Structure-based design of potent, conformationally constrained Smac mimetics. *Journal of the American Chemical Society*, **2004**, 126, 16686-7	16.4	143
7	Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. *Journal of Medicinal Chemistry*, **2004**, 47, 4147-50	8.3	131
6	Instantaneous normal mode analysis of hydrated electron solvation dynamics. *Journal of Chemical Physics*, **2001**, 114, 3598-3611	3.9	37
5	Structural and Electronic Characterization of Chemical and Conformational Defects in Conjugated Polymers. *Journal of Physical Chemistry B*, **2001**, 105, 6103-6107	3.4	70
4	Electron propagation along a nanowire: a study in chattering. *Nanotechnology*, **1998**, 9, 365-368	3.4	
3	Accurate variational calculations and analysis of the HOCl vibrational energy spectrum. *Journal of Chemical Physics*, **1998**, 109, 10273-10283	3.9	64
2	The effect of angular momentum on the unimolecular dissociation HCO-þH+CO. *Journal of Chemical Physics*, **1997**, 107, 7773-7786	3.9	24
1	Basic Principles and Practices of Computer-Aided Drug Design259-278		